JP2004503213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004503213A5 JP2004503213A5 JP2001571699A JP2001571699A JP2004503213A5 JP 2004503213 A5 JP2004503213 A5 JP 2004503213A5 JP 2001571699 A JP2001571699 A JP 2001571699A JP 2001571699 A JP2001571699 A JP 2001571699A JP 2004503213 A5 JP2004503213 A5 JP 2004503213A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- mhc class
- acid sequence
- acid construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 102000043129 MHC class I family Human genes 0.000 description 24
- 108091054437 MHC class I family Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 20
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 5
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 5
- 102000047279 human B2M Human genes 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53496600A | 2000-03-27 | 2000-03-27 | |
| PCT/IL2001/000260 WO2001072768A2 (en) | 2000-03-27 | 2001-03-19 | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004503213A JP2004503213A (ja) | 2004-02-05 |
| JP2004503213A5 true JP2004503213A5 (enExample) | 2008-02-21 |
Family
ID=24132253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001571699A Pending JP2004503213A (ja) | 2000-03-27 | 2001-03-19 | １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US7399838B2 (enExample) |
| EP (2) | EP1294748B1 (enExample) |
| JP (1) | JP2004503213A (enExample) |
| AT (1) | ATE472601T1 (enExample) |
| AU (1) | AU785493B2 (enExample) |
| CA (1) | CA2404489A1 (enExample) |
| DE (1) | DE60142475D1 (enExample) |
| IL (1) | IL151860A0 (enExample) |
| WO (1) | WO2001072768A2 (enExample) |
| ZA (1) | ZA200207515B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1294748B1 (en) * | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| GB0115071D0 (en) * | 2001-06-20 | 2001-08-15 | Avidex Ltd | Substances |
| US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US20030199024A1 (en) * | 2002-04-19 | 2003-10-23 | Hansen Ted H. | Single chain trimers of class I MHC molecules |
| US8895020B2 (en) * | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| WO2003106616A2 (en) * | 2002-06-12 | 2003-12-24 | Gavish-Galilee Bio Applications Ltd | MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES |
| US20090075304A1 (en) * | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090233318A1 (en) * | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
| US20090264319A1 (en) * | 2004-06-03 | 2009-10-22 | Masumi Abe | Method for the analysis of exclusive gene expression profile using a trace amount of sample |
| US20100062001A1 (en) * | 2004-06-09 | 2010-03-11 | Technion Research & Development | Antibodies for selective apoptosis of cells |
| US8518697B2 (en) | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| WO2007136778A2 (en) * | 2006-05-19 | 2007-11-29 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
| US8394590B2 (en) * | 2006-08-02 | 2013-03-12 | California Institute Of Technology | Capture agents and related methods and systems for detecting and/or sorting targets |
| CA2682093A1 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
| WO2009125394A1 (en) | 2008-04-09 | 2009-10-15 | Technion Research & Development Foundation Ltd. | Anti human immunodeficiency antibodies and uses thereof |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| EP2184297A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G polypeptides and pharmaceutical uses thereof |
| DK2699593T4 (da) * | 2011-04-20 | 2021-02-08 | Univ Washington Through Its Center For Commercialization | Beta-2 mikroglobulin-deficiente celler |
| PL2723773T3 (pl) * | 2011-06-22 | 2018-07-31 | F.Hoffmann-La Roche Ag | Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I |
| EP4253409A3 (en) | 2012-04-17 | 2023-12-06 | University of Washington through its Center for Commercialization | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| MA50819A (fr) | 2014-12-23 | 2021-04-07 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| IL301919A (en) | 2015-03-27 | 2023-06-01 | Immatics Biotechnologies Gmbh | Innovative peptides and a combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| CN114456272A (zh) | 2015-04-03 | 2022-05-10 | 优瑞科生物技术公司 | 靶向afp肽/mhc复合体的构建体及其用途 |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| IL281396B (en) | 2015-06-09 | 2022-07-01 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| PT3319985T (pt) | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| PE20181583A1 (es) | 2016-03-01 | 2018-10-04 | Immatics Biotechnologies Gmbh | Peptido recombinante derivado de la proteina duoxa2 |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| SG10202110335PA (en) | 2016-04-06 | 2021-10-28 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| TW201831517A (zh) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
| WO2018138257A1 (en) | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| CR20210160A (es) | 2017-04-10 | 2021-04-26 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508) |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| KR20200026898A (ko) | 2017-07-07 | 2020-03-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| CN111727262A (zh) | 2017-07-25 | 2020-09-29 | 加州理工学院 | 胞啃介导的表位发现 |
| US11535651B2 (en) | 2017-08-02 | 2022-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hepatitis B nanoparticle-based vaccine for influenza virus |
| KR102802061B1 (ko) * | 2017-11-10 | 2025-05-02 | 주라 바이오, 인크. | 주 조직적합성 복합체-기반 키메라 수용체 및 자가면역 질병을 치료하기 위한 이의 용도 |
| GB201802338D0 (en) | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| KR20200137548A (ko) | 2019-05-30 | 2020-12-09 | 에스케이하이닉스 주식회사 | 메모리 장치 및 이의 테스트 동작 방법 |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| CA3124457A1 (en) | 2018-12-21 | 2020-06-25 | Biontech Us Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
| EP4021493A1 (en) | 2019-08-29 | 2022-07-06 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | T cell epitopes of hcmv and uses of thereof |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| WO2024124232A1 (en) * | 2022-12-09 | 2024-06-13 | Advanced Rna Vaccine (Arv) Technologies, Inc. | Nucleic acid based cancer vaccine and methods thereof |
| EP4761754A2 (en) | 2023-08-18 | 2026-06-24 | Immatics Biotechnologies GmbH | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| CA1192510A (en) | 1981-05-27 | 1985-08-27 | Lawrence E. Pelcher | Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom |
| JPS6054684A (ja) | 1983-09-05 | 1985-03-29 | Teijin Ltd | 新規ｄνａ及びハイブリツドｄνａ |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| CA1288073C (en) | 1985-03-07 | 1991-08-27 | Paul G. Ahlquist | Rna transformation vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| GB8608850D0 (en) | 1986-04-11 | 1986-05-14 | Diatech Ltd | Packaging system |
| JPS6314693A (ja) | 1986-07-04 | 1988-01-21 | Sumitomo Chem Co Ltd | 植物ウイルスｒｎａベクタ− |
| ES2060646T3 (es) | 1987-02-09 | 1994-12-01 | Lubrizol Genetics Inc | Virus rna hibrido. |
| US5316931A (en) | 1988-02-26 | 1994-05-31 | Biosource Genetics Corp. | Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes |
| US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
| US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6153408A (en) * | 1991-11-15 | 2000-11-28 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
| US6011146A (en) * | 1991-11-15 | 2000-01-04 | Institut Pasteur | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5837477A (en) * | 1993-01-15 | 1998-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptor ligands and methods of using same |
| US5874239A (en) * | 1993-07-30 | 1999-02-23 | Affymax Technologies N.V. | Biotinylation of proteins |
| US5820866A (en) * | 1994-03-04 | 1998-10-13 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for T cell regulation |
| US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| JPH11507843A (ja) * | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| US6140113A (en) * | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
| US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US6248564B1 (en) * | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
| EP1294748B1 (en) * | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| US8022190B2 (en) * | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| US7362707B2 (en) * | 2001-07-23 | 2008-04-22 | Acme Packet, Inc. | System and method for determining flow quality statistics for real-time transport protocol data flows |
| US6843882B2 (en) * | 2002-07-15 | 2005-01-18 | Applied Materials, Inc. | Gas flow control in a wafer processing system having multiple chambers for performing same process |
| WO2007136778A2 (en) * | 2006-05-19 | 2007-11-29 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
-
2001
- 2001-03-19 EP EP01914159A patent/EP1294748B1/en not_active Expired - Lifetime
- 2001-03-19 JP JP2001571699A patent/JP2004503213A/ja active Pending
- 2001-03-19 AT AT01914159T patent/ATE472601T1/de not_active IP Right Cessation
- 2001-03-19 CA CA002404489A patent/CA2404489A1/en active Pending
- 2001-03-19 AU AU39534/01A patent/AU785493B2/en not_active Ceased
- 2001-03-19 DE DE60142475T patent/DE60142475D1/de not_active Expired - Lifetime
- 2001-03-19 IL IL15186001A patent/IL151860A0/xx unknown
- 2001-03-19 EP EP10166544A patent/EP2316950A1/en not_active Withdrawn
- 2001-03-19 WO PCT/IL2001/000260 patent/WO2001072768A2/en not_active Ceased
-
2002
- 2002-02-13 US US10/073,300 patent/US7399838B2/en not_active Expired - Fee Related
- 2002-02-15 US US10/075,257 patent/US20040086960A1/en not_active Abandoned
- 2002-09-19 ZA ZA200207515A patent/ZA200207515B/en unknown
-
2008
- 2008-06-18 US US12/213,368 patent/US20090148925A1/en not_active Abandoned
-
2009
- 2009-06-18 US US12/486,794 patent/US20090258393A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102826762B1 (ko) | 생체자기 마이크로스피어 및 이의 제조 방법과 용도 | |
| US20090035814A1 (en) | Method for producing circular or multimeric protein species in vivo or in vitro and related methods | |
| FI109810B (fi) | Menetelmä rekombinanttiproteiinien entsymaattiseksi pilkkomiseksi käyttämällä IgA-proteaaseja | |
| CA2378871A1 (en) | Design of beta-sheet proteins with specific binding properties | |
| FI113547B (fi) | Geloniinia koodaava synteettinen geeni ja välineitä ja menetelmiä geenin ja proteiinin tuottamiseksi | |
| JP2007530435A5 (enExample) | ||
| JPH11504506A (ja) | 酵母における安定な抗体フラグメントの生産 | |
| JP2023502335A (ja) | スプリットインテインシステムを使用したタンパク質精製 | |
| JP2004537312A (ja) | 核酸−蛋白質融合多量体のモジュラーアッセンブリ | |
| JP4005633B2 (ja) | Ｆ型ボツリヌス毒素およびその用途 | |
| EP1981978B1 (en) | Affinity polypeptide for purification of recombinant proteins | |
| CN103789319A (zh) | 一种绿盲蝽超气门蛋白、其编码序列、载体和菌株 | |
| CN112851771A (zh) | 连接核酸与蛋白或肽的方法 | |
| CN113480613B (zh) | 一种自剪切蛋白标签、改造方法及其应用 | |
| CN103965341B (zh) | 一种细菌结合蛋白、其编码基因、以此基因为目的基因生产的融合蛋白及其应用 | |
| CN102153651A (zh) | 抗葡聚糖单链抗体及其制备方法 | |
| CN114716563B (zh) | 一种融合蛋白及其制备与应用 | |
| CN120518757B (zh) | 一种聚乙二醇化多价抗西尼罗病毒单链抗体 | |
| CN114480346B (zh) | 一种dna水解酶及其制备方法 | |
| CN100443503C (zh) | 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素 | |
| TWI712691B (zh) | 葡聚醣親和性標籤及其應用 | |
| JP2005527194A5 (enExample) | ||
| HK40081489A (en) | Biomagnetic microsphere and preparation method therefor and use thereof | |
| RS61384B1 (sr) | Postupak dobijanja proteina sa više epitopa kao i vektora dnk za izvođenje ovog postupka | |
| CN107964039A (zh) | 一种重组GP96-ScFv蛋白及其制备方法和应用 |